IP Litigation for the Life Sciences & HealthTech Sector

Our strengths include:

• BPCIA and Hatch-Waxman litigation
• Innovator vs. innovator biopharma litigation
• Emerging fields of innovation, including CRISPR, CAR T and bispecific antibody disputes

We Know Our Way Around the Courtroom

Over the past five years, we have handled more than 270 patent litigations, 164 PTAB proceedings, 18 ITC investigations and 32 federal circuit appeals. In addition, our IPR success rate is substantially higher than the industry average, with an 86.4% win rate for patentees.

Precedent-Setting Wins

Our team has prevailed in several recent precedent-setting matters for the industry. For example, we upended a $1.2 billion judgment against Kite Pharma, a Gilead subsidiary, in a patent battle with Juno Therapeutics over a CAR T patent. We also racked up a district court and Federal Circuit victory for Kite Pharma in a massively high-stakes appeal against Idenix Pharmaceuticals involving a $2.5 billion patent judgment.

Hatch-Waxman and BPCIA Experience

Our litigators bring experience defending innovators in hundreds of life sciences district court cases, including dozens of Hatch-Waxman (ANDA and 505(b)(2)) litigations and BPCIA (biosimilar) litigations, as well as life sciences matters before the ITC and the PTAB.

Emerging Science

We have particular strength in emerging fields of innovation, including bispecific antibody, CRISPR, CAR T, gene therapy and next generation sequencing disputes, as well as general biopharma and medical device litigation.

Life Sciences Technical Degrees

Our IP team includes 57 lawyers with technical degrees in life sciences and engineering and 7 PhDs – so we understand our life sciences clients’ inventions and how to explain them to juries and judges.

Strong Appellate Record

We take the results through appeal, led by our Chambers Band 1-ranked IP Appellate team, and draw on a roster of 11 former Federal Circuit clerks with 8 of today’s active Federal Circuit judges and 10 former SCOTUS clerks.